Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality
Top Cited Papers
- 29 March 2020
- journal article
- research article
- Published by Elsevier BV in International Journal of Antimicrobial Agents
- Vol. 55 (5), 105954
- https://doi.org/10.1016/j.ijantimicag.2020.105954
Abstract
No abstract availableKeywords
This publication has 56 references indexed in Scilit:
- Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid LeukemiaThe New England Journal of Medicine, 2013
- mTORC1 inhibition restricts inflammation-associated gastrointestinal tumorigenesis in miceJCI Insight, 2013
- PROGNOSTIC VALUE OF INTERLEUKIN 6, PROCALCITONIN, AND C-REACTIVE PROTEIN LEVELS IN INTENSIVE CARE UNIT PATIENTS DURING FIRST INCREASE OF FEVERShock, 2006
- Interleukin-6 and its receptor: from bench to bedsideMedical Microbiology and Immunology, 2006
- Multilevel Regulation of IL‐6R by IL‐6–sIL‐6R Fusion Protein According to the Primitiveness of Peripheral Blood‐Derived CD133+CellsThe International Journal of Cell Cloning, 2006
- The expression of membrane protein augments the specific responses induced by SARS-CoV nucleocapsid DNA immunizationMolecular Immunology, 2006
- Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cellsNature, 2006
- Humanized anti–interleukin-6 receptor antibody treatment of multicentric Castleman diseaseBlood, 2005
- Principles of interleukin (IL)-6-type cytokine signalling and its regulationBiochemical Journal, 2003
- Cloning and Expression of the Human Interleukin-6 (BSF-2/IFNβ 2) ReceptorScience, 1988